JP6283320B2 - ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 - Google Patents
ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 Download PDFInfo
- Publication number
- JP6283320B2 JP6283320B2 JP2014556041A JP2014556041A JP6283320B2 JP 6283320 B2 JP6283320 B2 JP 6283320B2 JP 2014556041 A JP2014556041 A JP 2014556041A JP 2014556041 A JP2014556041 A JP 2014556041A JP 6283320 B2 JP6283320 B2 JP 6283320B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- PBNWEDWXMJZREX-UHFFFAOYSA-N CC1=NC(C)=CS2C1C2 Chemical compound CC1=NC(C)=CS2C1C2 PBNWEDWXMJZREX-UHFFFAOYSA-N 0.000 description 1
- 0 CCCC(CCO)(C1)[C@]1Nc1c(CN(CC2)C(c3c[s]c(C)n3)=*)c2nc(N)n1 Chemical compound CCCC(CCO)(C1)[C@]1Nc1c(CN(CC2)C(c3c[s]c(C)n3)=*)c2nc(N)n1 0.000 description 1
- OXYLSEGFCZHCPR-UHFFFAOYSA-N CCCCNc1c(CN(CC2)C(C3CCC3)=O)c2nc(N)n1 Chemical compound CCCCNc1c(CN(CC2)C(C3CCC3)=O)c2nc(N)n1 OXYLSEGFCZHCPR-UHFFFAOYSA-N 0.000 description 1
- UEUDJVVHQQCTQJ-UHFFFAOYSA-N CCCCNc1nc(N)nc(C2)c1CCN2C(C1=CC=CC1CCC)=O Chemical compound CCCCNc1nc(N)nc(C2)c1CCN2C(C1=CC=CC1CCC)=O UEUDJVVHQQCTQJ-UHFFFAOYSA-N 0.000 description 1
- RYJBSWANUOUDDD-AWEZNQCLSA-N CCCC[C@@H](CCO)Nc1nc(N)nc(C2)c1CCN2C(c1ccc[n]1C)=O Chemical compound CCCC[C@@H](CCO)Nc1nc(N)nc(C2)c1CCN2C(c1ccc[n]1C)=O RYJBSWANUOUDDD-AWEZNQCLSA-N 0.000 description 1
- RKUYNGIBWIWGFR-NSHDSACASA-N CCC[C@@H](CCO)Nc1c(CN(CC2)C(c3c[s]cn3)=O)c2nc(N)n1 Chemical compound CCC[C@@H](CCO)Nc1c(CN(CC2)C(c3c[s]cn3)=O)c2nc(N)n1 RKUYNGIBWIWGFR-NSHDSACASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12154474 | 2012-02-08 | ||
| EP12154474.6 | 2012-02-08 | ||
| PCT/EP2013/052372 WO2013117615A1 (en) | 2012-02-08 | 2013-02-07 | Piperidino-pyrimidine derivatives for the treatment of viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506380A JP2015506380A (ja) | 2015-03-02 |
| JP6283320B2 true JP6283320B2 (ja) | 2018-02-21 |
Family
ID=47678822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556041A Expired - Fee Related JP6283320B2 (ja) | 2012-02-08 | 2013-02-07 | ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9133192B2 (show.php) |
| EP (1) | EP2812331B1 (show.php) |
| JP (1) | JP6283320B2 (show.php) |
| KR (1) | KR102064807B1 (show.php) |
| CN (1) | CN104245695B (show.php) |
| AU (1) | AU2013218072B2 (show.php) |
| BR (1) | BR112014019699B1 (show.php) |
| CA (1) | CA2862823C (show.php) |
| CL (1) | CL2014002093A1 (show.php) |
| DK (1) | DK2812331T3 (show.php) |
| EA (2) | EA033907B1 (show.php) |
| ES (1) | ES2716811T3 (show.php) |
| IL (1) | IL233499B (show.php) |
| IN (1) | IN2014MN01736A (show.php) |
| MX (1) | MX357296B (show.php) |
| MY (1) | MY169159A (show.php) |
| NZ (1) | NZ627036A (show.php) |
| PH (1) | PH12014501738B1 (show.php) |
| SG (1) | SG11201404743TA (show.php) |
| UA (1) | UA112668C2 (show.php) |
| WO (1) | WO2013117615A1 (show.php) |
| ZA (1) | ZA201405820B (show.php) |
Families Citing this family (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3330257B1 (en) | 2011-04-08 | 2020-03-11 | Janssen Sciences Ireland Unlimited Company | Pyrimidine derivatives for the treatment of viral infections |
| AU2012334127B2 (en) | 2011-11-09 | 2017-05-18 | Janssen Sciences Ireland Uc | Purine derivatives for the treatment of viral infections |
| JP6283320B2 (ja) | 2012-02-08 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 |
| PT2872515T (pt) | 2012-07-13 | 2016-07-27 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para o tratamento de infeções virais |
| EP2906563B1 (en) | 2012-10-10 | 2018-02-28 | Janssen Sciences Ireland UC | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
| CA2886635C (en) | 2012-11-16 | 2021-01-05 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| ES2733361T3 (es) | 2013-02-21 | 2019-11-28 | Janssen Sciences Ireland Unlimited Co | Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas |
| WO2014154859A1 (en) | 2013-03-29 | 2014-10-02 | Janssen R&D Ireland | Macrocyclic deaza-purinones for the treatment of viral infections |
| KR102280559B1 (ko) | 2013-05-24 | 2021-07-22 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 및 추가적인 질환의 치료를 위한 피리돈 유도체 |
| WO2014207082A1 (en) | 2013-06-27 | 2014-12-31 | Janssen R&D Ireland | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
| EP3027624B1 (en) | 2013-07-30 | 2018-09-12 | Janssen Sciences Ireland UC | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
| MY199988A (en) | 2015-03-04 | 2023-12-02 | Gilead Sciences Inc | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| JP2018525412A (ja) | 2015-08-26 | 2018-09-06 | ギリアード サイエンシーズ， インコーポレイテッド | 重水素化トール様受容体調節因子 |
| HK1257270A1 (zh) * | 2015-09-15 | 2019-10-18 | Gilead Sciences, Inc. | 用於治療hiv的toll樣受體(tlr)調節劑 |
| MY196200A (en) | 2015-12-15 | 2023-03-22 | Gilead Sciences Inc | Human Immunodeficiency Virus Neutralizing Antibodies |
| JP6770098B2 (ja) | 2016-05-27 | 2020-10-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法 |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| CN109476675B (zh) * | 2016-07-01 | 2022-12-09 | 爱尔兰詹森科学公司 | 用于治疗病毒性感染的二氢吡喃并嘧啶衍生物 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| MA46093A (fr) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| PE20190732A1 (es) * | 2016-09-09 | 2019-05-23 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
| KR102450287B1 (ko) | 2016-09-29 | 2022-09-30 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그 |
| KR20210118240A (ko) | 2016-10-14 | 2021-09-29 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AU2018319538B9 (en) | 2017-08-22 | 2021-05-27 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CN111065636B (zh) * | 2017-09-22 | 2022-08-23 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基衍生物、其制备方法及其在医药上的应用 |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| KR20200100113A (ko) | 2017-12-15 | 2020-08-25 | 실버백 테라퓨틱스, 인크. | 간염 치료용 항체 구조물-약물 접합체 |
| EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| ES2956288T3 (es) | 2018-02-16 | 2023-12-18 | Gilead Sciences Inc | Métodos y productos intermedios para preparar un compuesto terapéutico útil en el tratamiento de infección vírica por Retroviridae |
| EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| TWI772370B (zh) * | 2018-02-26 | 2022-08-01 | 瑞士商諾華公司 | 作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物 |
| TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CA3097312A1 (en) | 2018-05-18 | 2019-11-21 | Novartis Ag | Crystalline forms of a tlr7/tlr8 inhibitor |
| KR102579246B1 (ko) | 2018-07-03 | 2023-09-19 | 길리애드 사이언시즈, 인코포레이티드 | HIV gp120을 표적화하는 항체 및 사용 방법 |
| JP7199502B2 (ja) | 2018-07-06 | 2023-01-05 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| WO2020010200A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| TWI809427B (zh) | 2018-07-13 | 2023-07-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| MX2021002764A (es) | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| ES2979163T3 (es) | 2018-10-31 | 2024-09-24 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1 |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| CN119462659A (zh) | 2019-03-22 | 2025-02-18 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其药学用途 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| CA3141085A1 (en) | 2019-06-19 | 2020-12-24 | Brenda Stevens | Anti-mesothelin antibodies and immunoconjugates thereof |
| KR102776925B1 (ko) | 2019-06-25 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| IL315295A (en) | 2019-09-30 | 2024-10-01 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| CA3153501A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CA3157275A1 (en) | 2019-11-26 | 2021-06-03 | Elena BEKERMAN | Capsid inhibitors for the prevention of hiv |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| PH12022551441A1 (en) | 2019-12-24 | 2023-11-20 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds |
| CR20220396A (es) | 2020-02-14 | 2022-11-14 | Jounce Therapeutics Inc | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| US20240043427A1 (en) | 2020-05-01 | 2024-02-08 | Gilead Sciences, Inc. | Cd73 compounds |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| CR20220559A (es) | 2020-05-04 | 2023-08-18 | Vigil Neuroscience Inc | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| TW202502766A (zh) | 2020-06-25 | 2025-01-16 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| JP7690222B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
| CR20230071A (es) | 2020-08-07 | 2023-04-11 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| PT4244396T (pt) | 2020-11-11 | 2025-10-20 | Gilead Sciences Inc | Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120 |
| EP4319820A1 (en) | 2021-04-10 | 2024-02-14 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202308699A (zh) | 2021-04-23 | 2023-03-01 | 美商普方生物製藥美國公司 | Ｃｄ７０結合劑、其結合物及其使用方法 |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN118369316A (zh) | 2021-12-03 | 2024-07-19 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
| SI4445900T1 (sl) | 2021-12-03 | 2025-09-30 | Gilead Sciences, Inc. | Terapevtske spojine za okužbo z virusom hiv |
| JP7765637B2 (ja) | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| CN118382625A (zh) * | 2021-12-08 | 2024-07-23 | 上海维申医药有限公司 | 作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物 |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240034724A1 (en) | 2022-07-01 | 2024-02-01 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| CA3265134A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| KR20250172591A (ko) | 2023-04-19 | 2025-12-09 | 길리애드 사이언시즈, 인코포레이티드 | 캡시드 저해제의 투여 레지먼 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250011352A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| TW202519517A (zh) | 2023-07-26 | 2025-05-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| US20250120989A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202530226A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025260028A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ329798A (en) | 1996-07-03 | 1999-04-29 | Japan Energy Corp | Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same |
| DE69817393T2 (de) | 1997-11-28 | 2004-06-17 | Sumitomo Pharmaceuticals Co., Ltd. | Neue heterozyklische verbindungen |
| ATE267175T1 (de) * | 1998-08-27 | 2004-06-15 | Sumitomo Pharma | Pyrimidin derivate |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| JPWO2003104230A1 (ja) * | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | 二環性ピリミジン誘導体 |
| US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
| WO2006117670A1 (en) | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
| PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| EA201001264A1 (ru) | 2008-02-07 | 2011-04-29 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7 |
| EA201101650A1 (ru) * | 2009-05-21 | 2012-07-30 | Астразенека Аб | Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний |
| US8637525B2 (en) * | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI468402B (zh) * | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| JP2013032290A (ja) * | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| JP6283320B2 (ja) | 2012-02-08 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 |
-
2013
- 2013-02-07 JP JP2014556041A patent/JP6283320B2/ja not_active Expired - Fee Related
- 2013-02-07 KR KR1020147022432A patent/KR102064807B1/ko not_active Expired - Fee Related
- 2013-02-07 EA EA201491486A patent/EA033907B1/ru unknown
- 2013-02-07 BR BR112014019699-0A patent/BR112014019699B1/pt not_active IP Right Cessation
- 2013-02-07 EA EA201992133A patent/EA039373B1/ru unknown
- 2013-02-07 NZ NZ627036A patent/NZ627036A/en not_active IP Right Cessation
- 2013-02-07 AU AU2013218072A patent/AU2013218072B2/en not_active Ceased
- 2013-02-07 IN IN1736MUN2014 patent/IN2014MN01736A/en unknown
- 2013-02-07 CA CA2862823A patent/CA2862823C/en active Active
- 2013-02-07 MX MX2014009556A patent/MX357296B/es active IP Right Grant
- 2013-02-07 SG SG11201404743TA patent/SG11201404743TA/en unknown
- 2013-02-07 WO PCT/EP2013/052372 patent/WO2013117615A1/en not_active Ceased
- 2013-02-07 CN CN201380008467.4A patent/CN104245695B/zh active Active
- 2013-02-07 EP EP13703055.7A patent/EP2812331B1/en active Active
- 2013-02-07 MY MYPI2014002281A patent/MY169159A/en unknown
- 2013-02-07 DK DK13703055.7T patent/DK2812331T3/en active
- 2013-02-07 ES ES13703055T patent/ES2716811T3/es active Active
- 2013-02-07 US US14/377,064 patent/US9133192B2/en active Active
- 2013-07-02 UA UAA201407816A patent/UA112668C2/uk unknown
-
2014
- 2014-07-03 IL IL233499A patent/IL233499B/en active IP Right Grant
- 2014-08-01 PH PH12014501738A patent/PH12014501738B1/en unknown
- 2014-08-07 ZA ZA2014/05820A patent/ZA201405820B/en unknown
- 2014-08-07 CL CL2014002093A patent/CL2014002093A1/es unknown
-
2015
- 2015-08-04 US US14/818,094 patent/US9365571B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6283320B2 (ja) | ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 | |
| JP6302906B2 (ja) | ウイルス感染および他の疾患を治療するためのアルキルピリミジン誘導体 | |
| JP6293765B2 (ja) | ウイルス感染症および他の疾患の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体 | |
| JP6401788B2 (ja) | ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体 | |
| JP2019524662A (ja) | ウイルス感染治療用のジヒドロピラノピリミジン | |
| AU2013326579A1 (en) | 1,2,4-triazine derivatives for the treatment of viral infections. | |
| JP6377139B2 (ja) | ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体 | |
| HK1201254B (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| HK40003405A (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| HK1207636B (zh) | 用於治疗病毒感染和另外的疾病的烷基嘧啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150814 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151105 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160830 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170606 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180109 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180126 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6283320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |